The mutation of splicing factor U2AF1 and relative aberrant AS events were identified in multiple cancer types (24), while splicing factor SF3B1 was suggested to be a therapeutic target for breast cancer patients (25). This evidence concerns the gene SLU7 and breast carcinoma.